Moneycontrol PRO

you are here: HomeNewsBusinessCompaniesMay surpass FY14 rev guidance by 5%: Dishman Pharma

SHOW NAMES

Trending Topics

business

May surpass FY14 rev guidance by 5%: Dishman Pharma

JR Vyas, CMD, Dishman Pharma said the sale of SEZ land is likely to be concluded in the next fiscal.

first published: Dec 31, 2013 01:52 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Live: Positive start to November series, Nifty sustains above 26,000 | Closing Bell
Live: Will Nifty continue to chase 26,000? | Opening Bell
Stock Market LIVE: Sensex, Nifty Off Day’s Lows | F&O Expiry Sparks Volatility | Closing Bell
‘Ashoka University Won’t Expand to Other Cities’ | Pramath Raj Sinha & Ashish Dhawan LIVE

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347